Relapsed Hematologic Malignancy Patients Vulnerable to COVID-19
نویسندگان
چکیده
منابع مشابه
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
PURPOSE Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in he...
متن کاملHematologic Parameters of COVID – 19: A Review on Alteration of Hematologic Laboratory Findings
Corona virus 2019 (COVID –19) is a public health emergency and according to the recent statistic of World Health Organization (WHO), this novel virus has infected all continents. During this outbreak, there is an urgent need for documentation of laboratory predictors to discriminate between mild and severe forms of this virus. In this pandemic, prompt identification of clinical and labora...
متن کاملImmunotherapy of hematologic malignancy.
Over the past few years, improved understanding of the molecular basis of interactions between antigen presenting cells and effector cells and advances in informatics have both led to the identification of many candidate antigens that are targets for immunotherapy. However, while immunotherapy has successfully eradicated relapsed hematologic malignancy after allogeneic transplant as well as vir...
متن کاملGenomics of Hematologic Malignancy
(58 articles) Reviews in Translational Hematology (4217 articles) Neoplasia (149 articles) Genomics (1086 articles) Gene Expression Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: htt...
متن کاملRadioimmunotherapy with radretumab in patients with relapsed hematologic malignancies.
UNLABELLED We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. METHODS Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed l...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2021
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000735136.72338.84